A review on experimental and clinical genetic associations studies on fear conditioning, extinction and cognitive-behavioral treatment

Translational Psychiatry

Volumn 1, Issue , 2011, Pages

  Lonsdorf, T B ^a   Kalisch, R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

anxiety; cognitive behavioral treatment; conditioning; exposure; extinction; genetics

Indexed keywords

ANXIETY DISORDER; CONDITIONING; FEAR; GENETIC ASSOCIATION; GENETICS; HUMAN; PHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL ASPECT; REINFORCEMENT; REVIEW;

ANXIETY DISORDERS; CONDITIONING (PSYCHOLOGY); EXTINCTION, PSYCHOLOGICAL; FEAR; GENETIC ASSOCIATION STUDIES; HUMANS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 80053259538     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.36     Document Type: Review

References (99)

1. Ohman A, Mineka S. Fears, phobias, and preparedness: Toward an evolved module of fear and fear learning. Psychol Rev 2001; 108: 483-522. (Pubitemid 33604135)
2. Mineka S, Zinbarg R. A contemporary learning theory perspective on the etiology of anxiety disorders-It's not what you thought it was. Am Psychol 2006; 61: 10-26. (Pubitemid 43134219)
3. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev 2001; 108: 4-32. (Pubitemid 33604124)
4. Lissek S, Powers A, McClure E, Phelps E, Woldehawariat G, Grillon C et al. Classical fear conditioning in the anxiety disorders: A meta-analysis. Behav Res Ther 2005; 43: 1391-1424. (Pubitemid 41282795)
5. Anderson KC, Insel TR. The promise of extinction research for the prevention and treatment of anxiety disorders. Biol Psychiatry 2006; 60: 319-321. (Pubitemid 44215858)
6. Foa EB, Franklin ME, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 2002; 52: 987-997.
7. Otto M, Smits J, Reese H. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry 2004; 65: 34-41.
8. Linden DEJ. How psychotherapy changes the brain-the contribution of functional neuroimaging. Mol Psychiatry 2006; 11: 528-538.
9. Kandel ER. Biology and the future of psychoanalysis: A new intellectual framework for psychiatry revisited. Am J Psychiatry 1999; 156: 505-524. (Pubitemid 29162970)
10. Hettema JM, Annas P, Neale MC, Kendler KS, Fredrikson M. A twin study of the genetics of fear conditioning. Arch Gen Psychiatry 2003; 60: 702-708. (Pubitemid 36818632)
11. Merrill KA, Steinmetz JE, Viken RJ, Rose RJ. Genetic influences on human conditionability: A twin study of the conditioned eyeblink response. Behav Genet 1999; 29: 95-102. (Pubitemid 29295740)
12. Royce JR. Avoidance conditioning in nine strains of inbred mice using optimal stimulus parameters. Behav Genet 1972; 2: 107-110.
13. Gordon JA, Hen R. Genetic approaches to the study of anxiety. Annu Rev Neurosci 2004; 27: 193-222. (Pubitemid 39050402)
14. Fanselow M, Poulos A. The neuroscience of mammalian associative learning. Annu Rev Psychol 2005; 56: 207-234. (Pubitemid 40300784)
15. Myers K, Davis M. Behavioral and neural analysis of extinction. Neuron 2002; 36: 567-584. (Pubitemid 35346753)
16. Mechias M-L, Etkin A, Kalisch R. A meta-analysis of instructed fear studies: Implications for conscious appraisal of threat. NeuroImage 2010; 49: 1760-1768.
17. Lesch K, Mossner R. Genetically driven variation in serotonin uptake: Is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998; 44: 179-192. (Pubitemid 28378300)
18. Berry M, Juorio A, Paterson I. The functional-role of monoamine oxidase-A and oxidase-B in the mammalian central-nervous-system. Progr Neurobiol 1994; 42: 375-391.
19. Heils A, Teufel A, Petri S, Seemann M, Bengel D, Balling U et al. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect 1995; 102: 247-254. (Pubitemid 26010732)
20. Parsey R, Hastings R, Oquendo M, Hu X, Goldman D, Huang Y et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006; 163: 48-51. (Pubitemid 43050102)
21. Reimold M, Smolka M, Schumann G, Zimmer A, Wrase J, Mann K et al. Midbrain serotonin transporter binding potential measured with [C-11]DASB is affected by serotonin transporter genotype. J Neural Transm 2007; 114: 635-639. (Pubitemid 46664049)
22. Van Dyck C, Malison R, Staley J, Jacobsen L, Seibyl J, Laruelle M et al. Central serotonin transporter availability measured with [I-123]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004; 161: 525-531. (Pubitemid 38326108)
23. Nordquist N, Oreland L. Serotonin, genetic variability, behaviour, and psychiatric disorders-a review. Ups J Med Sci 2010; 115: 2-10.
24. Kraft J, Slager S, McGrath P, Hamilton S. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374-381. (Pubitemid 41219705)
25. Wendland J, Martin B, Kruse M, Lesch K, Murphy D. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 2006; 11: 224-226.
26. Hu X, Lipsky R, Zhu G, Akhtar L, Taubman J, Greenberg B et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815-826.
27. Garpenstrand H, Annas P, Ekblom J, Oreland L, FredriksonM. Human fear conditioning is related to dopaminergic and serotonergic biological markers. Behav Neurosci 2001; 115: 358-364. (Pubitemid 32378165)
28. Lonsdorf T, Weike A, Nikamo P, Schalling M, Hamm A, Ohman A. Genetic gating of human fear learning and extinction: Possible implications for gene-environment interaction in anxiety disorder. Psychol Sci 2009; 20: 198-206.
29. Crisan L, Pana S, Vulturar R, Heilman R, Szekely R, Druga B et al. Genetic contributions of the serotonin transporter to social learning of fear and economic decision making. Soc Cogn Affect Neurosci 2009; 4: 399-408.
30. Olsson A, Nearing K, Phelps E. Learning fears by observing others: The neural systems of social fear transmission. Soc Cogn Affect Neurosci 2007; 2: 3-11. (Pubitemid 47090788)
31. Blechert J, Michael T, Vriends N, Margraf J, Wilhelm F. Fear conditioning in posttraumatic stress disorder: Evidence for delayed extinction of autonomic, experiential, and behavioural responses. Behav Res Ther 2007; 45: 2019-2033. (Pubitemid 47210952)
32. Kilpatrick D, Koenen K, Ruggiero K, Acierno R, Galea S, Resnick H et al. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am J Psychiatry 2007; 164: 1693-1699. (Pubitemid 350205346)
33. Koenen K, Aiello A, Bakshis E, Amstadter A, Ruggiero K, Acierno R et al. Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. Am J Epidemiol 2009; 169: 704-711.
34. Kolassa I, Ertl V, Eckart C, Glockner F, Kolassa S, Papassotiropoulos A et al. Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: Evidence from survivors of the Rwandan genocide. J Clin Psychiatry 2010a; 71: 543-547.
35. Bryant RA, Felmingham KL, Falconer EM, Pe Benito L, Dobson-Stone C, Pierce KD et al. Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry 2010; 67: 1217-1219.
36. Lonsdorf T, Ruck C, Bergstrom J, Andersson G, Ohman A, Schalling M et al. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Progr Neuro-Psychopharmacol Biol Psychiatry 2009; 33: 1479-1483.
37. Lonsdorf TB, Rück C, Bergström J, Andersson G, Ohman A, Lindefors N et al. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010a; 10: 99.
38. Sabol S, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103: 273-279. (Pubitemid 28470076)
39. Deckert J, Catalano M, Syagailo Y, Bosi M, Okladnova O, Di Bella D et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8: 621-624. (Pubitemid 29139976)
40. Mannisto P, Kaakkola S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593-628.
41. Tenhunen J, Salminen M, Lundström K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994; 223: 1049-1059. (Pubitemid 24263190)
42. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-omethyltransferase activity in man. Am J Hum Genet 1977; 29: 125-135. (Pubitemid 8070429)
43. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006; 60: 141-151.
44. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O- methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943-1961. (Pubitemid 39486546)
45. Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: Differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 2004; 161: 359-361. (Pubitemid 38419288)
46. Raczka KA, Mechias M-L, Gartmann N, Reif A, Deckert J, Pessiglione M et al. Empirical support for an involvement of the meso-striataldopamine system in human fear extinction. Transl Psychiatry 2011; 1: E12; doi:10.1038/tp.2011.10.
47. LaLumiere RT, Nawar EM, McGaugh JL. Modulation of memory consolidation by the basolateral amygdala or nucleus accumbens shell requires concurrent dopamine receptor activation in both brain regions. Learn Mem 2005; 12: 296-301. (Pubitemid 40958340)
48. Kolassa I-T, Kolassa S, Ertl V, Papassotiropoulos A, De Quervain DJ-F. The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-omethyltransferase Val(158)Met polymorphism. Biol Psychiatry 2010b; 67: 304-308.
49. Plomin R, DeFries JC, Loehlin JC. Genotype-environment interaction and correlation in the analysis of human behavior. Psychol Bull 1977; 84: 309-322.
50. Valente NLM, Vallada H, Cordeiro Q, Bressan RA, Andreoli SB, Mari JJ et al. Catechol-O-methyltransferase (COMT) val158met polymorphism as a risk factor for PTSD after urban violence. J Mol Neurosci [Internet] 2010; available from: Http://www.ncbi.nlm.nih.gov/ pubmed/2108010 (cited 16 February 2011).
51. Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends Neurosci 2004; 27: 270-277. (Pubitemid 38529955)
52. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001; 1: 152-156. (Pubitemid 33757602)
53. VanNess S, Owens M, Kilts C. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 2005; 6: 55.
54. Miller GM, Madras BK. Polymorphisms in the 30-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 2002; 7: 44-55. (Pubitemid 34087878)
55. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133-139. (Pubitemid 30016015)
56. Mill J, Asherson P, Craig I, D'Souza U. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 2005; 6: 3.
57. Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB et al. Prediction of dopamine transporter binding availability by genotype: A preliminary report. Am J Psychiatry 2000; 157: 1700-1703.
58. Van Dyck C, Malison R, Staley J, Jacobsen L, Seibyl J, Laruelle M et al. Central serotonin transporter availability measured with [I-123]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004; 161: 525-531. (Pubitemid 38326108)
59. Schultz W. Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 2006; 57: 87-115. (Pubitemid 43237228)
60. Duan J, Wainwright M, Comeron J, Saitou N, Sanders A, Gelernter J et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12: 205-216. (Pubitemid 36204418)
61. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 2009; 63: 907-912.
62. Huertas E, Ponce G, Koeneke M, Poch C, Espana-Serrano L, Palomo T et al. The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming. Genes Brain Behav 2010; 9: 103-109.
63. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-152.
64. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157-1165.
65. Ding Y-C, Chi H-C, Grady DL, Morishima A, Kidd JR, Kidd KK et al. Evidence of positive selection acting at the human dopamine receptor D4 gene locus. Proc Natl Acad Sci USA 2002; 99: 309-314. (Pubitemid 34060359)
66. Wang E, Ding Y-C, Flodman P, Kidd JR, Kidd KK, Grady DL et al. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet 2004; 74: 931-944. (Pubitemid 38568966)
67. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
68. Chen Z-Y, Patel PD, Sant G, Meng C-X, Teng KK, Hempstead BL et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24: 4401-4411. (Pubitemid 38608151)
69. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269. (Pubitemid 36144114)
70. Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res 2000; 128: 231-241. (Pubitemid 35461239)
71. Rattiner LM, Davis M, Ressler KJ. Brain-derived neurotrophic factor in amygdaladependent learning. Neuroscientist 2005; 11: 323-333. (Pubitemid 41040861)
72. Hajcak G, Castille C, Olvet D, Dunning J, Roohi J, Hatchwell E. Genetic variation in brain-derived neurotrophic factor and human fear conditioning. Genes Brain Behav 2009; 8: 80-85.
73. Lonsdorf T, Weike A, Golkar A, Schalling M, Hamm A, Ohman A. Amygdala-dependent fear conditioning in humans is modulated by the BDNFval66met polymorphism. Behav Neurosci 2010b; 124: 9-15.
74. Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 2010; 327: 863-866.
75. Raczka K, Gartmann N, Mechias M, Reif A, Buchel C, Deckert J et al. A neuropeptide S receptor variant associated with overinterpretation of fear reactions: A potential neurogenetic basis for catastrophizing. Mol Psychiatry 2010; 15: 1067-1074.
76. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23: 540-545. (Pubitemid 38720604)
77. Jonsson E, Nothen M, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296. (Pubitemid 29292183)
78. Pohjalainen T, Rinne J, Nagren K, Lehikoinen P, Anttila K, Syvalahti E et al. The A1 allele of the human D-2 dopamine receptor gene predicts low D-2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260. (Pubitemid 28266335)
79. Huertas E, Ponce G, Koeneke M, Poch C, Espana-Serrano L, Palomo T et al. The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming. Genes Brain Behav 2010; 9: 103-109.
80. Reinscheid RK, Xu Y-L, Civelli O. Neuropeptide S: A new player in the modulation of arousal and anxiety. Mol Interv 2005; 5: 42-46. (Pubitemid 40467774)
81. Bernier V, Stocco R, Bogusky M, Joyce J, Parachoniak C, Grenier K et al. Structure-function relationships in the neuropeptide S receptor-molecular consequences of the asthma-associated mutation N107I. J Biol Chem 2006; 281: 24704-24712. (Pubitemid 44274244)
82. Reinscheid R, Xu Y, Okamura N, Zeng J, Chung S, Pai R et al. Pharmacological characterization of human and murine neuropeptide S receptor variants. J Pharmacol Exp Therap 2005; 315: 1338-1345. (Pubitemid 41635423)
83. Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P et al. Neuropeptide S receptor gene-converging evidence for a role in panic disorder. Mol Psychiatry [Internet] 2010; available from: Http://dx.doi.org/10.1038/mp. 2010.81 (cited 6 January 2011).
84. Beck A, ff EG, Greenberg RLR. Anxiety Disorders, Phobias. Basic Books: New York, 1985.
85. Reiss S, McNally R. Theoretical issues in behavior therapy. Reiss S, Bootzin RR (eds). In: The Expectancy Model of Fear. Academic Press: New York, 1985, pp 107-122.
86. Miyata A, Arimura A, Dahl R, Minamino N, Uehara A, Jiang L et al. Isolation of a novel-38 residue-hypothalamic polypeptide which stimulates adenylate-cyclase in pituitary-cells. Biochem Biophys Res Commun 1989; 164: 567-574. (Pubitemid 19269770)
87. Ressler K, Mercer K, Bradley B, Jovanovic T, Mahan A, Kerley K et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011; 470: 492-497.
88. Hamm AO, Greenwald MK, Bradley MM, Lang PJ. Emotional learning, hedonic change, and the startle probe. J Abnorm Psychol 1993; 102: 453-465. (Pubitemid 23264188)
89. Skolnick AI, Davidson RI. Affective modulation of eyeblink startle with reward and threat. Psychophysiology 2002; 39: 835-850.
90. Crowne DP, Marlowe D. A new scale of social desirability independent of psychopathology. J Consult Psychol 1960; 24: 349-354.
91. Myers KM, Ressler KJ, Davis M. Different mechanisms of fear extinction dependent on length of time since fear acquisition. Learn Mem 2006; 13: 216-223.
92. Huff NC, Hernandez JA, Blanding NQ, LaBar KS. Delayed extinction attenuates conditioned fear renewal and spontaneous recovery in humans. Behav Neurosci 2009; 123: 834-843.
93. Norrholm SD, Vervliet B, Jovanovic T, Boshoven W, Myers KM, Davis M et al. Timing of extinction relative to acquisition: A parametric analysis of fear extinction in humans. Behav Neurosci 2008; 122: 1016-1030.
94. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E et al. STrengthening the reporting of genetic association studies (STREGA): An extension of the STROBE statement. Ann Intern Med 2009; 150: 206-215.
95. Plendl W, Wotjak C. Dissociation of within-and between-session extinction of conditioned fear. J Neurosci 2010; 30: 4990-4998.
96. Le-Niculescu H, Balaraman Y, Patel SD, Ayalew M, Gupta J, Kuczenski R et al. Convergent functional genomics of anxiety disorders: Translational identification of genes, biomarkers, pathways and mechanisms. Transl Psychiatry 2011; 1: E9.
97. Grillon C.-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms. Biol Psychiatry 2009; 66: 636-641.
98. de Quervain DJ-F, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J et al. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci [Internet] 2011; available from: Http://www.pnas.org/content/early/2011/03/ 14/1018214108.abstract (cited 5 May 2011).
99. Bechara A, Tranel D, Damasio H, Adolphs R, Rockland C, Damasio AR. Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. Science 1995; 269: 1115-1118.